EUVIMEDEUVIMED entdecken
Crossref

Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case‐Control Study Based on the Roxadustat User Population

Ruijie Man, Yufeng Li, Yue Zhang, Xiaochong Zhu, Hongdong Huang iD

Therapeutic Apheresis and Dialysis · 2026-08 · 30 (4) · 511-522

DOI: 10.1002/1744-9987.70139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 08.04.2026. Verfasst von Ruijie Man und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Isoquinolines, Glycine, Renal Dialysis, Renal Insufficiency, Chronic. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic kidney disease (CKD) often necessitates maintenance hemodialysis, a process associated with significant complications such as bleeding and thromboembolic events. Roxadustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor, is emerging as a promising alternative for managing anemia in CKD. This study aims to assess risk factors for bleeding and thromboembolic events in CKD patients on hemodialysis, focusing on Roxadustat use.

Methods

We conducted a retrospective case‐control study of 229 CKD patients undergoing maintenance hemodialysis for at least 1 year. Patients were categorized based on the occurrence of bleeding ( n = 51) or thromboembolic events ( n = 58), compared to those without such events ( n = 120). Baseline demographics, laboratory markers, and Roxadustat usage were evaluated. Logistic regression analyses were used to identify independent risk factors for bleeding and thromboembolic events.

Results

Roxadustat usage was significantly less common in patients who experienced bleeding events (64.71%) compared to the no occurrence group (85.00%, p = 0.003), and similarly less common in those with thromboembolic events (67.24%) compared to the no occurrence group (85.00%, p = 0.006). Lower baseline hemoglobin levels were associated with bleeding events ( p = 0.007), while higher baseline hemoglobin levels were associated with thromboembolic events ( p = 0.008). Elevated baseline hs‐CRP levels were significant in both the bleeding group ( p = 0.001) and thromboembolic group ( p = 0.019). TSAT below 30% at baseline was also a significant factor in both the bleeding group ( p = 0.004) and thromboembolic group ( p = 0.025). Multivariate analyses indicated that Roxadustat use significantly reduced bleeding risk (OR = 0.376, p = 0.024) and thromboembolic events (OR = 0.287, p = 0.003).

Conclusion

Roxadustat use was associated with a lower risk of bleeding and thromboembolic events in CKD patients on hemodialysis. This association may be mediated through the stabilization of hemoglobin levels, modulation of iron metabolism, and attenuation of inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoquinolinesGlycineRenal DialysisRenal Insufficiency, ChronicThromboembolismHemorrhageHumansRetrospective StudiesFemaleMaleRisk FactorsCase-Control StudiesAgedMiddle AgedLogistic ModelsAnemiaProlyl-Hydroxylase Inhibitors

Stichwörter der Autor:innen

Roxadustatbleedingchronic kidney diseasehemodialysisrisk factorsthromboembolic events

Substanzen

IsoquinolinesGlycineroxadustatProlyl-Hydroxylase Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Nephrology Department, Qinhuangdao Haigang Hospital, Qinhuangdao, Hebei, China.

ORCID-Profile: Hongdong Huang

Zitieren

APA

Man, R., Li, Y., Zhang, Y., Zhu, X., & Huang, H. (2026). Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case‐Control Study Based on the Roxadustat User Population. Therapeutic Apheresis and Dialysis, 30(4), 511-522. https://doi.org/10.1002/1744-9987.70139

Vancouver

Man R, Li Y, Zhang Y, Zhu X, Huang H. Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case‐Control Study Based on the Roxadustat User Population. Therapeutic Apheresis and Dialysis. 2026;30(4):511-522. doi:10.1002/1744-9987.70139

BibTeX
@article{Man2026,
  author = {Man, Ruijie and Li, Yufeng and Zhang, Yue and Zhu, Xiaochong and Huang, Hongdong},
  title = {Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case‐Control Study Based on the Roxadustat User Population},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  volume = {30},
  number = {4},
  pages = {511--522},
  doi = {10.1002/1744-9987.70139}
}
Kostenlos starten →